March 24, 2020
Takeda Pharmaceutical said on March 23 that its inflammatory bowel disease treatment Entyvio (vedolizumab) has been approved by the Chinese regulatory body, National Medical Products Administration (NMPA), for the treatment of ulcerative colitis (UC) or Crohn’s disease (CD). Entyvio, a...read more